296 related articles for article (PubMed ID: 17268543)
1. Treatment with biologic therapies and the risk of cancer in patients with IBD.
Biancone L; Calabrese E; Petruzziello C; Pallone F
Nat Clin Pract Gastroenterol Hepatol; 2007 Feb; 4(2):78-91. PubMed ID: 17268543
[TBL] [Abstract][Full Text] [Related]
2. Safety of infliximab and other biologic agents in the inflammatory bowel diseases.
Reddy JG; Loftus EV
Gastroenterol Clin North Am; 2006 Dec; 35(4):837-55. PubMed ID: 17129816
[TBL] [Abstract][Full Text] [Related]
3. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials.
Lichtenstein GR; Diamond RH; Wagner CL; Fasanmade AA; Olson AD; Marano CW; Johanns J; Lang Y; Sandborn WJ
Aliment Pharmacol Ther; 2009 Aug; 30(3):210-26. PubMed ID: 19392858
[TBL] [Abstract][Full Text] [Related]
4. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease.
Cottone M; Kohn A; Daperno M; Armuzzi A; Guidi L; D'Inca R; Bossa F; Angelucci E; Biancone L; Gionchetti P; Ardizzone S; Papi C; Fries W; Danese S; Riegler G; Cappello M; Castiglione F; Annese V; Orlando A
Clin Gastroenterol Hepatol; 2011 Jan; 9(1):30-5. PubMed ID: 20951835
[TBL] [Abstract][Full Text] [Related]
5. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality.
Caspersen S; Elkjaer M; Riis L; Pedersen N; Mortensen C; Jess T; Sarto P; Hansen TS; Wewer V; Bendtsen F; Moesgaard F; Munkholm P;
Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1212-7; quiz 1176. PubMed ID: 18848503
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study.
Fidder H; Schnitzler F; Ferrante M; Noman M; Katsanos K; Segaert S; Henckaerts L; Van Assche G; Vermeire S; Rutgeerts P
Gut; 2009 Apr; 58(4):501-8. PubMed ID: 18832524
[TBL] [Abstract][Full Text] [Related]
7. How to improve the safety of biologic therapy in Crohn's disease.
Ferkolj I
J Physiol Pharmacol; 2009 Dec; 60 Suppl 7():67-70. PubMed ID: 20388947
[TBL] [Abstract][Full Text] [Related]
8. Minimizing infliximab toxicity in the treatment of inflammatory bowel disease.
Orlando A; Mocciaro F; Civitavecchia G; Scimeca D; Cottone M
Dig Liver Dis; 2008 Jul; 40 Suppl 2():S236-46. PubMed ID: 18598995
[TBL] [Abstract][Full Text] [Related]
9. Infliximab use in children and adolescents with inflammatory bowel disease.
de Ridder L; Benninga MA; Taminiau JA; Hommes DW; van Deventer SJ
J Pediatr Gastroenterol Nutr; 2007 Jul; 45(1):3-14. PubMed ID: 17592358
[TBL] [Abstract][Full Text] [Related]
10. Adverse effects of biologics used for treating IBD.
Stallmach A; Hagel S; Bruns T
Best Pract Res Clin Gastroenterol; 2010 Apr; 24(2):167-82. PubMed ID: 20227030
[TBL] [Abstract][Full Text] [Related]
11. Safety issues with biological therapies for inflammatory bowel disease.
Van Assche G; Vermeire S; Rutgeerts P
Curr Opin Gastroenterol; 2006 Jul; 22(4):370-6. PubMed ID: 16760752
[TBL] [Abstract][Full Text] [Related]
12. Use of immunomodulators and biologic therapies in children with inflammatory bowel disease.
Bousvaros A
Expert Rev Clin Immunol; 2010 Jul; 6(4):659-66. PubMed ID: 20594138
[TBL] [Abstract][Full Text] [Related]
13. Refractory Takayasu arteritis successfully treated with infliximab.
Maffei S; Di Renzo M; Santoro S; Puccetti L; Pasqui AL
Eur Rev Med Pharmacol Sci; 2009; 13(1):63-5. PubMed ID: 19364087
[TBL] [Abstract][Full Text] [Related]
14. Emerging biological treatments in inflammatory bowel diseases.
Van Assche G; Vermeire S; Rutgeerts P
Dig Dis; 2006; 24(1-2):131-6. PubMed ID: 16699271
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy.
Passarini B; Infusino SD; Barbieri E; Varotti E; Gionchetti P; Rizzello F; Morselli C; Tambasco R; Campieri M
Dermatology; 2007; 215(4):295-300. PubMed ID: 17911986
[TBL] [Abstract][Full Text] [Related]
16. [Chronic inflammatory bowel disease - new therapies: tumor necrosis factor-antibodies and cytokines].
Stange EF
Z Gastroenterol; 2002 Apr; 40 Suppl 1():S90-S1. PubMed ID: 11930299
[TBL] [Abstract][Full Text] [Related]
17. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease.
Fiorino G; Allez M; Malesci A; Danese S
Aliment Pharmacol Ther; 2009 May; 29(9):921-7. PubMed ID: 19210297
[TBL] [Abstract][Full Text] [Related]
18. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
Aringer M; Houssiau F; Gordon C; Graninger WB; Voll RE; Rath E; Steiner G; Smolen JS
Rheumatology (Oxford); 2009 Nov; 48(11):1451-4. PubMed ID: 19748965
[TBL] [Abstract][Full Text] [Related]
19. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety.
Van Assche G; Lewis JD; Lichtenstein GR; Loftus EV; Ouyang Q; Panes J; Siegel CA; Sandborn WJ; Travis SP; Colombel JF
Am J Gastroenterol; 2011 Sep; 106(9):1594-602; quiz 1593, 1603. PubMed ID: 21844919
[TBL] [Abstract][Full Text] [Related]
20. Assessing response and loss of response to biological therapies in IBD.
Yanai H; Hanauer SB
Am J Gastroenterol; 2011 Apr; 106(4):685-98. PubMed ID: 21427713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]